China Trading Desk Launches Comprehensive China Travel Dashboard Amid Rising Outbound Travel
25.7.2023 10:27:00 EEST | Business Wire | Press release
China Trading Desk, a premier provider of marketing and advertising solutions for the Chinese market, is proud to announce the release of our game-changing tool - the China Travel Dashboard. Built to provide unparalleled insights into the evolving attitudes, expectations, and behaviours of outbound travellers from China, this dashboard is born out of our deep understanding of the Chinese market, a sector that has witnessed a remarkable upward trajectory in recent years.
Our newly launched China Travel Dashboard is designed to act as a compass, helping our clients navigate the complexity of this dynamic market. The dashboard brings a treasure trove of critical information to your fingertips, transforming it into a must-have tool for formulating and executing digital marketing campaigns aimed at Chinese tourists.
Here's a quick overview of the unique modules the China Travel Dashboard encompasses:
- Travel Sentiment: This module features an exhaustive quarterly survey helmed by China Trading Desk, assessing the travel inclinations of potential Chinese outbound travellers, thereby providing a snapshot of emerging trends.
- Pre-Trip: Developed in partnership with VariFlight, this module delivers real-time travel data including daily airport traffic flow from all airports in China to a selected group of 25 countries around the world, providing a glimpse into preferred destinations.
- In-Trip: Partnering with UnionPay, this module offers an exclusive window into Chinese tourists' spending patterns and preferences while they're immersed in their travel experiences.
Subramania Bhatt, Founder & CEO of China Trading Desk, stated, "We are thrilled to bring this comprehensive tool to our esteemed clients. The China Travel Dashboard is a solid reflection of our relentless commitment to staying on the cutting edge of providing data that's most relevant for our advertisers and agencies. As the outbound travel market in China continues to expand, we are confident this tool will prove to be indispensable in aiding businesses and advertisers to effectively understand, reach, and engage with Chinese tourists."
The dashboard’s data allows businesses to formulate personalized marketing strategies, optimize ad scheduling, undertake destination marketing, predict upcoming trends, and facilitate product development. Notably, several renowned brands including a global luxury conglomerate and the world's largest hospitality chain, have beta-tested the Dashboard and acclaimed it as the most comprehensive tool to understand Chinese travel insights and behaviour.
For more information visit the China Travel Dashboard.
About China Trading Desk:
China Trading Desk is a marketing technology company enabling brands & agencies to help advertise in China & across the world. Our suite of products focuses on China advertising and Chinese travellers and enables advertisers to effectively reach out to their target audience. CTD works with some of the world’s most pioneering brands including Singapore Airlines, HSBC, LVMH Group, Qatar Airways, etc. We are headquartered in Singapore with offices in Hong Kong, Shanghai, Shenzhen, Guangzhou, and affiliates in Dubai, London and New York.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230724321638/en/
Contact information
China Trading Desk
Marketing Department
+6566992226
Hello@chinatradingdesk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom